Abstract
Background: Oxidative/antioxidant imbalance is considered a causal cause of diminished ovarian reserve (DOR). 8-oxyguanine DNA glycosylase (OGG1) has been reported to act as an antioxidant by binding non-catalytically to oxidation-induced DNA damage in the promoter region.
Objective: This study aimed to evaluate serum OGG1 concentrations in patients with or without DOR and to explore the clinical value of OGG1 as a novel diagnostic indicator for DOR.
Methods: Sixty-four women with DOR and seventy-eight women with normal ovarian reserve (NOR) from the reproductive medical center of Renmin Hospital of Wuhan University were included. Enzyme-linked immunosorbent assay (ELISA) kits were used to determine serum OGG1 levels in patients on 2-5 days of the menstrual cycle. Data regarding the enrolled patients were also obtained from the database of the hospital, including age, body mass index (BMI), anti-Müllerian hormone (AMH), etc.
Results: OGG1 levels were increased in the DOR group (2.08 ± 0.70 vs 1.46 ± 0.47 nmol/L, P < 0.001) and negatively correlated with AMH levels (Spearman r = -0.586, P < 0.001). After adjusting for age and BMI, a negative association between OGG1 and AMH remained (β = -0.619, P < 0.001). ROC curve analysis showed that a cut-off value of 1.765 nmol/L had an appropriate sensitivity (81.30%) and specificity (76.90%) for discriminating individuals with and without DOR, with the area under the curve (95% CI) of 0.870 (0.814 to 0.926), P < 0.001.
Conclusion: We determined that serum OGG1 levels might be suggested as a new diagnostic indicator for DOR.
Keywords: Diminished ovarian reserve, oxidative stress, 8-oxoguanine DNA glycosylase, anti-Müllerian hormone, folliclestimulating hormone, diagnostic.
Graphical Abstract
[http://dx.doi.org/10.1016/j.fertnstert.2020.09.134] [PMID: 33280722]
[http://dx.doi.org/10.2147/DDDT.S279553] [PMID: 33239863]
[http://dx.doi.org/10.1007/s43032-019-00005-8] [PMID: 32046374]
[http://dx.doi.org/10.1186/s12958-020-00670-4] [PMID: 33198782]
[http://dx.doi.org/10.1071/RD18472] [PMID: 31656219]
[http://dx.doi.org/10.1002/jcp.30468] [PMID: 34121193]
[http://dx.doi.org/10.3389/fphar.2020.617843] [PMID: 33569007]
[http://dx.doi.org/10.1038/s41419-018-0680-0] [PMID: 29795387]
[http://dx.doi.org/10.1016/j.lfs.2020.117886] [PMID: 32497631]
[http://dx.doi.org/10.1096/fj.201902243R] [PMID: 32378256]
[http://dx.doi.org/10.1016/j.repbio.2020.04.005] [PMID: 32387020]
[http://dx.doi.org/10.1093/humrep/der092] [PMID: 21505041]
[http://dx.doi.org/10.1016/j.ejogrb.2009.05.008] [PMID: 19487066]
[PMID: 34384322]
[http://dx.doi.org/10.1155/2021/9999659] [PMID: 34122613]
[http://dx.doi.org/10.1007/s10815-020-01793-8] [PMID: 32451813]
[http://dx.doi.org/10.18632/oncotarget.23916] [PMID: 29435182]
[http://dx.doi.org/10.1186/s12958-021-00825-x] [PMID: 34521427]
[http://dx.doi.org/10.1016/j.toxlet.2016.04.008] [PMID: 27091075]
[http://dx.doi.org/10.1186/1471-2407-13-253] [PMID: 23697596]
[http://dx.doi.org/10.1155/2021/8817858] [PMID: 34135985]
[http://dx.doi.org/10.1016/j.biopha.2019.108963] [PMID: 31125824]
[http://dx.doi.org/10.4049/jimmunol.1401625] [PMID: 25267977]
[http://dx.doi.org/10.1016/j.freeradbiomed.2011.10.490] [PMID: 22100973]
[http://dx.doi.org/10.1159/000442287] [PMID: 26682912]
[http://dx.doi.org/10.1074/jbc.M611295200] [PMID: 17355977]
[http://dx.doi.org/10.18632/aging.104123] [PMID: 33223510]
[http://dx.doi.org/10.1016/j.mce.2017.10.002] [PMID: 28986302]
[http://dx.doi.org/10.1016/j.fertnstert.2013.07.588]
[PMID: 29105397]
[http://dx.doi.org/10.1159/000484392] [PMID: 29073627]
[http://dx.doi.org/10.1095/biolreprod67.2.361] [PMID: 12135868]